TRETINOIN Side Effects

6992582-0 | Cerebral Haemorrhage, Disease Progression, Disseminated Intravascular Coagulation
on Sep 09, 2010 Female patient from AUSTRALIA , 67 years of age, was treated with Tretinoin (View Usage). Patient experienced the following unwanted or unexpected effects: cerebral haemorrhage, disease progression, disseminated intravascular coagulation. Tretinoin dosage: . During the same period patient was treated with PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), IDARUBICIN HCL (View Idarubicin Hcl Review and Idarubicin Hcl Label ).

6921688-7 | Kerion
Patient was taking Tretinoin (View Usage). Patient had the following side effects: kerion on Aug 03, 2010 from ITALY Additional patient health information: Female patient , 28 years of age, was diagnosed with alopecia areata and. Tretinoin dosage: 40 Day Course. During the same period patient was treated with MINOXIDIL (40 Day Course) (View Minoxidil Review and Minoxidil Label ), BETAMETHASONE VALERATE (40 Day Course) (View Betamethasone Valerate Review and Betamethasone Valerate Label ).

6746423-7 | Acute Myeloid Leukaemia, Cytogenetic Abnormality, Hepatic Function Abnormal, Myelodysplastic Syndrome
Adverse event was reported on May 17, 2010 by a Male patient taking Tretinoin (View Usage) (Dosage: ) was diagnosed with acute promyelocytic leukaemia and. Location: AUSTRALIA , 54 years of age, After Tretinoin was administered, patient had the following side effects: acute myeloid leukaemia, cytogenetic abnormality, hepatic function abnormal, myelodysplastic syndrome. During the same period patient was treated with IDARUBICIN HCL (View Idarubicin Hcl Review and Idarubicin Hcl Label ), MERCAPTOPURINE (View Mercaptopurine Review and Mercaptopurine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ).

6746411-0 | Acute Myeloid Leukaemia, Cytogenetic Abnormality, Myelodysplastic Syndrome
on May 17, 2010 Female patient from AUSTRALIA , 29 years of age, was treated with Tretinoin (View Usage). Patient experienced the following unwanted or unexpected effects: acute myeloid leukaemia, cytogenetic abnormality, myelodysplastic syndrome. Tretinoin dosage: . During the same period patient was treated with IDARUBICIN HCL (View Idarubicin Hcl Review and Idarubicin Hcl Label ), MERCAPTOPURINE (View Mercaptopurine Review and Mercaptopurine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ).


6741772-0 | Acute Myeloid Leukaemia, Cytogenetic Abnormality, Myelodysplastic Syndrome
on May 17, 2010 Male patient from AUSTRALIA , 50 years of age, was treated with Tretinoin (View Usage). Patient had the following side effects: acute myeloid leukaemia, cytogenetic abnormality, myelodysplastic syndrome. Tretinoin dosage: . During the same period patient was treated with IDARUBICIN HCL (View Idarubicin Hcl Review and Idarubicin Hcl Label ), MERCAPTOPURINE (View Mercaptopurine Review and Mercaptopurine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ).

6737974-X | Cytogenetic Abnormality, Hepatic Function Abnormal
Patient was taking Tretinoin (View Usage). After Tretinoin was administered, patient had the following side effects: cytogenetic abnormality, hepatic function abnormal on May 17, 2010 from AUSTRALIA Additional patient health information: Male patient , 60 years of age, . Tretinoin dosage: . During the same period patient was treated with IDARUBICIN HCL (View Idarubicin Hcl Review and Idarubicin Hcl Label ), MERCAPTOPURINE (View Mercaptopurine Review and Mercaptopurine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ).

6737973-8 | Cytogenetic Abnormality
Adverse event was reported on May 17, 2010 by a Male patient taking Tretinoin (View Usage) (Dosage: ) . Location: AUSTRALIA , 43 years of age, Patient experienced the following unwanted or unexpected effects: cytogenetic abnormality. During the same period patient was treated with IDARUBICIN HCL (View Idarubicin Hcl Review and Idarubicin Hcl Label ), MERCAPTOPURINE (View Mercaptopurine Review and Mercaptopurine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ).

6737972-6 | Cytogenetic Abnormality
on May 17, 2010 Female patient from AUSTRALIA , 30 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Tretinoin (View Usage). Patient had the following side effects: cytogenetic abnormality. Tretinoin dosage: . During the same period patient was treated with IDARUBICIN HCL (View Idarubicin Hcl Review and Idarubicin Hcl Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), MERCAPTOPURINE (View Mercaptopurine Review and Mercaptopurine Label ).

6737929-5 | Cytogenetic Abnormality
on May 17, 2010 Female patient from AUSTRALIA , 37 years of age, was treated with Tretinoin (View Usage). After Tretinoin was administered, patient had the following side effects: cytogenetic abnormality. Tretinoin dosage: . During the same period patient was treated with IDARUBICIN HCL (View Idarubicin Hcl Review and Idarubicin Hcl Label ), MERCAPTOPURINE (View Mercaptopurine Review and Mercaptopurine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ).

6737917-9 | Cytogenetic Abnormality
Patient was taking Tretinoin (View Usage). Patient experienced the following unwanted or unexpected effects: cytogenetic abnormality on May 17, 2010 from AUSTRALIA Additional patient health information: Male patient , 20 years of age, . Tretinoin dosage: . During the same period patient was treated with ARA C (View Ara-c Review and Ara-c Label ).

6737913-1 | Cytogenetic Abnormality, Hepatic Function Abnormal
Adverse event was reported on May 17, 2010 by a Female patient taking Tretinoin (View Usage) (Dosage: ) . Location: AUSTRALIA , 16 years of age, Patient had the following side effects: cytogenetic abnormality, hepatic function abnormal. During the same period patient was treated with IDARUBICIN HCL (View Idarubicin Hcl Review and Idarubicin Hcl Label ), MERCAPTOPURINE (View Mercaptopurine Review and Mercaptopurine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ).

6737903-9 | Cytogenetic Abnormality, Myelodysplastic Syndrome
on May 17, 2010 Male patient from AUSTRALIA , 50 years of age, was treated with Tretinoin (View Usage). After Tretinoin was administered, patient had the following side effects: cytogenetic abnormality, myelodysplastic syndrome. Tretinoin dosage: . During the same period patient was treated with IDARUBICIN HCL (View Idarubicin Hcl Review and Idarubicin Hcl Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), MERCAPTOPURINE (View Mercaptopurine Review and Mercaptopurine Label ).

6710073-9 | Neuropathy Peripheral, Skin Exfoliation
on Apr 22, 2010 Male patient from FRANCE , 16 years of age, was diagnosed with acne (What is acne?) and was treated with Tretinoin (View Usage). Patient experienced the following unwanted or unexpected effects: neuropathy peripheral, skin exfoliation. Tretinoin dosage: 1 Df; Hs; Top. Patient was hospitalized.

6678185-6 | Abasia, Contusion, Haemoptysis, Oxygen Saturation Decreased, Pain In Extremity, Pulmonary Haemorrhage, Swelling
Patient was taking Tretinoin (View Usage). Patient had the following side effects: abasia, contusion, haemoptysis, oxygen saturation decreased, pain in extremity, pulmonary haemorrhage, swelling on Apr 08, 2010 from UNITED STATES Additional patient health information: Male patient , weighting 162.7 lb, . Tretinoin dosage: 1320 Mg. During the same period patient was treated with CYTARABINE (2646 Mg) (View Cytarabine Review and Cytarabine Label ), DAUNORUBICIN HCL (388 Mg) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ). Patient was hospitalized.

6662201-1 | Neuropathy Peripheral
Adverse event was reported on Mar 18, 2010 by a Male patient taking Tretinoin (View Usage) (Dosage: ) was diagnosed with acne (What is acne?) and. Location: FRANCE , 16 years of age, After Tretinoin was administered, patient had the following side effects: neuropathy peripheral.

6631098-8 | Aspartate Aminotransferase Increased, Polyarteritis Nodosa
on Feb 22, 2010 Female patient from UNITED STATES , 19 years of age, was diagnosed with acne (What is acne?) and was treated with Tretinoin (View Usage). Patient experienced the following unwanted or unexpected effects: aspartate aminotransferase increased, polyarteritis nodosa. Tretinoin dosage: Topical. During the same period patient was treated with MINOCYCLINE HCL (50 To 100mg, Bid, Oral) (View Minocycline Hcl Review and Minocycline Hcl Label ), BENZAMYCIN (Topical) (View Benzamycin Review and Benzamycin Label ), BENZOYL PEROXIDE 10% GEL (Topical) (View Benzoyl Peroxide 10% Gel Review and Benzoyl Peroxide 10% Gel Label ), TRIPHASIC ETHINYL ESTRADIOL/NORGESTIMATE ORAL CONTRACEPTIVE PILLS (Oral) (View Triphasic Ethinyl Estradiol/norgestimate Oral Contraceptive Pills Review and Triphasic Ethinyl Estradiol/norgestimate Oral Contraceptive Pills Label ).

6631095-2 | Acne, Condition Aggravated, Hirsutism, Polyarteritis Nodosa
on Feb 22, 2010 Female patient from UNITED STATES , 20 years of age, was diagnosed with acne (What is acne?) and was treated with Tretinoin (View Usage). Patient had the following side effects: acne (What is acne?), condition aggravated, hirsutism, polyarteritis nodosa. Tretinoin dosage: Topical. During the same period patient was treated with MINOCYCLINE HCL (50 To 100mg, Bid, Oral) (View Minocycline Hcl Review and Minocycline Hcl Label ), BENZAMYCIN (View Benzamycin Review and Benzamycin Label ), BENZOYL PEROXIDE 6% GEL (View Benzoyl Peroxide 6% Gel Review and Benzoyl Peroxide 6% Gel Label ), ORAL CONTRACEPTIVE PILLS (TRIPHASIC ETHINYL ESTRADIOL/NORGESTIMATE) (View Oral Contraceptive Pills (triphasic Ethinyl Estradiol/norgestimate) Review and Oral Contraceptive Pills (triphasic Ethinyl Estradiol/norgestimate) Label ), ALBUTEROL SULATE (View Albuterol Sulate Review and Albuterol Sulate Label ).

6615795-6 | Neuropathy Peripheral
Patient was taking Tretinoin (View Usage). After Tretinoin was administered, patient had the following side effects: neuropathy peripheral on Feb 24, 2010 from FRANCE Additional patient health information: Male patient , 16 years of age, was diagnosed with acne (What is acne?) and. Tretinoin dosage: . Patient was hospitalized.

6607425-4 | Neuropathy Peripheral
Adverse event was reported on Feb 18, 2010 by a Male patient taking Tretinoin (View Usage) (Dosage: ) was diagnosed with acne (What is acne?) and. Location: FRANCE , 16 years of age, Patient experienced the following unwanted or unexpected effects: neuropathy peripheral. Patient was hospitalized.

6590477-8 | Acute Myeloid Leukaemia, Cytogenetic Abnormality, Myelodysplastic Syndrome
on Feb 11, 2010 Male patient from AUSTRALIA , 50 years of age, was treated with Tretinoin (View Usage). Patient had the following side effects: acute myeloid leukaemia, cytogenetic abnormality, myelodysplastic syndrome. Tretinoin dosage: . During the same period patient was treated with IDARUBICIN HCL (View Idarubicin Hcl Review and Idarubicin Hcl Label ), MERCAPTOPURINE (View Mercaptopurine Review and Mercaptopurine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ).

6590470-5 | Cytogenetic Abnormality
on Feb 11, 2010 Female patient from AUSTRALIA , 37 years of age, was treated with Tretinoin (View Usage). After Tretinoin was administered, patient had the following side effects: cytogenetic abnormality. Tretinoin dosage: . During the same period patient was treated with IDARUBICIN HCL (View Idarubicin Hcl Review and Idarubicin Hcl Label ), MERCAPTOPURINE (View Mercaptopurine Review and Mercaptopurine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ).

6590468-7 | Cytogenetic Abnormality
Patient was taking Tretinoin (View Usage). Patient experienced the following unwanted or unexpected effects: cytogenetic abnormality on Feb 11, 2010 from AUSTRALIA Additional patient health information: Male patient , 20 years of age, . Tretinoin dosage: . During the same period patient was treated with CYTARABINE (View Cytarabine Review and Cytarabine Label ).

6590467-5 | Cytogenetic Abnormality
Adverse event was reported on Feb 11, 2010 by a Female patient taking Tretinoin (View Usage) (Dosage: ) . Location: AUSTRALIA , 16 years of age, Patient had the following side effects: cytogenetic abnormality. During the same period patient was treated with MERCAPTOPURINE (View Mercaptopurine Review and Mercaptopurine Label ), IDARUBICIN HCL (View Idarubicin Hcl Review and Idarubicin Hcl Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ).

6590464-X | Acute Myeloid Leukaemia, Cytogenetic Abnormality, Myelodysplastic Syndrome
on Feb 11, 2010 Female patient from AUSTRALIA , 29 years of age, was treated with Tretinoin (View Usage). After Tretinoin was administered, patient had the following side effects: acute myeloid leukaemia, cytogenetic abnormality, myelodysplastic syndrome. Tretinoin dosage: . During the same period patient was treated with IDARUBICIN HCL (View Idarubicin Hcl Review and Idarubicin Hcl Label ), MERCAPTOPURINE (View Mercaptopurine Review and Mercaptopurine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ).

6590463-8 | Cytogenetic Abnormality, Myelodysplastic Syndrome
on Feb 11, 2010 Male patient from AUSTRALIA , 50 years of age, was treated with Tretinoin (View Usage). Patient experienced the following unwanted or unexpected effects: cytogenetic abnormality, myelodysplastic syndrome. Tretinoin dosage: . During the same period patient was treated with IDARUBICIN HCL (View Idarubicin Hcl Review and Idarubicin Hcl Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), MERCAPTOPURINE (View Mercaptopurine Review and Mercaptopurine Label ).

6590458-4 | Cytogenetic Abnormality
Patient was taking Tretinoin (View Usage). Patient had the following side effects: cytogenetic abnormality on Feb 11, 2010 from AUSTRALIA Additional patient health information: Male patient , 60 years of age, . Tretinoin dosage: . During the same period patient was treated with IDARUBICIN HCL (View Idarubicin Hcl Review and Idarubicin Hcl Label ), MERCAPTOPURINE (View Mercaptopurine Review and Mercaptopurine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ).

6590457-2 | Cytogenetic Abnormality
Adverse event was reported on Feb 11, 2010 by a Male patient taking Tretinoin (View Usage) (Dosage: ) . Location: AUSTRALIA , 43 years of age, After Tretinoin was administered, patient had the following side effects: cytogenetic abnormality. During the same period patient was treated with IDARUBICIN HCL (View Idarubicin Hcl Review and Idarubicin Hcl Label ), MERCAPTOPURINE (View Mercaptopurine Review and Mercaptopurine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ).

6590455-9 | Acute Myeloid Leukaemia, Cytogenetic Abnormality
on Feb 11, 2010 Male patient from AUSTRALIA , 54 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Tretinoin (View Usage). Patient experienced the following unwanted or unexpected effects: acute myeloid leukaemia, cytogenetic abnormality. Tretinoin dosage: . During the same period patient was treated with IDARUBICIN HCL (View Idarubicin Hcl Review and Idarubicin Hcl Label ), MERCAPTOPURINE (View Mercaptopurine Review and Mercaptopurine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ).

6590449-3 | Cytogenetic Abnormality
on Feb 11, 2010 Female patient from AUSTRALIA , 30 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Tretinoin (View Usage). Patient had the following side effects: cytogenetic abnormality. Tretinoin dosage: . During the same period patient was treated with IDARUBICIN HCL (View Idarubicin Hcl Review and Idarubicin Hcl Label ), MERCAPTOPURINE (View Mercaptopurine Review and Mercaptopurine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ).

6585831-4 | Retinal Detachment, Retinoic Acid Syndrome
Patient was taking Tretinoin (View Usage). After Tretinoin was administered, patient had the following side effects: retinal detachment, retinoic acid syndrome on Feb 16, 2010 from UNITED STATES Additional patient health information: Male patient , weighting 166.9 lb, . Tretinoin dosage: 2300 Mg. During the same period patient was treated with CYTARABINE (2604 Mg) (View Cytarabine Review and Cytarabine Label ), DAUNORUBICIN HCL (372 Mg) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ). Patient was hospitalized.

6584611-3 | Rash Erythematous, Treatment Failure
Adverse event was reported on Feb 13, 2010 by a Female patient taking Tretinoin (View Usage) (Dosage: 0.05% Qhs Apply To Face) was diagnosed with acne (What is acne?) and. Location: UNITED STATES , weighting 142.0 lb, Patient experienced the following unwanted or unexpected effects: rash erythematous, treatment failure.

6579020-7 | Retinoic Acid Syndrome
on Oct 15, 2009 Male patient from CHINA , 32 years of age, was diagnosed with psoriasis, rash (What is rash?) and was treated with Tretinoin (View Usage). Patient had the following side effects: retinoic acid syndrome. Tretinoin dosage: . During the same period patient was treated with VITAMIN (View Vitamin Review and Vitamin Label ), TRIS PISTIL (View Tris-pistil Review and Tris-pistil Label ), SORIATANE (20 Consecutive Days) (View Soriatane Review and Soriatane Label ). Patient was hospitalized.

6553557-9 | Acute Respiratory Distress Syndrome, Retinoic Acid Syndrome
on Jan 14, 2010 Male patient from TAIWAN, PROVINCE OF CHINA , 77 years of age, was treated with Tretinoin (View Usage). After Tretinoin was administered, patient had the following side effects: acute respiratory distress syndrome, retinoic acid syndrome. Tretinoin dosage: .

6553556-7 | Pulmonary Haemorrhage, Respiratory Failure, Retinoic Acid Syndrome
Patient was taking Tretinoin (View Usage). Patient experienced the following unwanted or unexpected effects: pulmonary haemorrhage, respiratory failure, retinoic acid syndrome on Jan 14, 2010 from TAIWAN, PROVINCE OF CHINA Additional patient health information: Female patient , 55 years of age, . Tretinoin dosage: . During the same period patient was treated with ARA C (View Ara-c Review and Ara-c Label ), DAUNORUBICIN HCL (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ).

6553554-3 | Pulmonary Haemorrhage, Respiratory Failure, Retinoic Acid Syndrome
Adverse event was reported on Jan 14, 2010 by a Female patient taking Tretinoin (View Usage) (Dosage: ) . Location: TAIWAN, PROVINCE OF CHINA , 27 years of age, Patient had the following side effects: pulmonary haemorrhage, respiratory failure, retinoic acid syndrome. During the same period patient was treated with PREDNISOLONE (View Prednisolone Review and Prednisolone Label ). Patient was hospitalized.

6534946-5 | Activities Of Daily Living Impaired, Confusional State, Fall, Impaired Self-care, Muscular Weakness
on Jan 11, 2010 Female patient from UNITED STATES , weighting 153.0 lb, was treated with Tretinoin (View Usage). After Tretinoin was administered, patient had the following side effects: activities of daily living impaired, confusional state, fall (What is fall?), impaired self-care, muscular weakness. Tretinoin dosage: 3000 Mg. During the same period patient was treated with CYTARABINE (2464 Mg) (View Cytarabine Review and Cytarabine Label ), DAUNORUBICIN HCL (352 Mg) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ). Patient was hospitalized.

6493538-7 | Intestinal Obstruction
on Nov 27, 2009 Male patient from GERMANY , 71 years of age, was diagnosed with myelodysplastic syndrome, refractory anaemia and was treated with Tretinoin (View Usage). Patient experienced the following unwanted or unexpected effects: intestinal obstruction. Tretinoin dosage: .

6493535-1 | Myocardial Infarction
Patient was taking Tretinoin (View Usage). Patient had the following side effects: myocardial infarction on Nov 27, 2009 from GERMANY Additional patient health information: Male patient , 81 years of age, was diagnosed with myelodysplastic syndrome and. Tretinoin dosage: .

6493518-1 | Pancreatitis
Adverse event was reported on Nov 27, 2009 by a Female patient taking Tretinoin (View Usage) (Dosage: ) was diagnosed with myelodysplastic syndrome, refractory anaemia and. Location: GERMANY , 58 years of age, After Tretinoin was administered, patient had the following side effects: pancreatitis.

6493517-X | Acute Myeloid Leukaemia
on Nov 27, 2009 Female patient from GERMANY , 71 years of age, was diagnosed with myelodysplastic syndrome, refractory anaemia with ringed sideroblasts and was treated with Tretinoin (View Usage). Patient experienced the following unwanted or unexpected effects: acute myeloid leukaemia. Tretinoin dosage: .

6493506-5 | Acute Myeloid Leukaemia
on Nov 27, 2009 Male patient from GERMANY , 47 years of age, was diagnosed with refractory anaemia, myelodysplastic syndrome and was treated with Tretinoin (View Usage). Patient had the following side effects: acute myeloid leukaemia. Tretinoin dosage: .

6493505-3 | Acute Myeloid Leukaemia
Patient was taking Tretinoin (View Usage). After Tretinoin was administered, patient had the following side effects: acute myeloid leukaemia on Nov 27, 2009 from GERMANY Additional patient health information: Male patient , 73 years of age, was diagnosed with myelodysplastic syndrome and. Tretinoin dosage: .

6445722-6 | Product Substitution Issue
Adverse event was reported on Nov 18, 2009 by a Female patient taking Tretinoin (View Usage) (Dosage: 0.05% Daily Skin) was diagnosed with acne (What is acne?) and. Location: UNITED STATES , 67 years of age, weighting 115.0 lb, Patient experienced the following unwanted or unexpected effects: product substitution issue.

6408448-0 | Erythrodermic Psoriasis, Retinoic Acid Syndrome
on Oct 15, 2009 Male patient from CHINA , 32 years of age, was diagnosed with psoriasis, rash (What is rash?) and was treated with Tretinoin (View Usage). Patient had the following side effects: erythrodermic psoriasis, retinoic acid syndrome. Tretinoin dosage: . During the same period patient was treated with VITAMIN (View Vitamin Review and Vitamin Label ), TRIS PISTIL (View Tris-pistil Review and Tris-pistil Label ), SORIATANE (View Soriatane Review and Soriatane Label ). Patient was hospitalized.

6296795-5 | Acute Myeloid Leukaemia, Acute Myeloid Leukaemia Recurrent, Malignant Neoplasm Progression, Osteomyelitis
on Jul 22, 2009 Male patient from PUERTO RICO , 32 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Tretinoin (View Usage). After Tretinoin was administered, patient had the following side effects: acute myeloid leukaemia, acute myeloid leukaemia recurrent, malignant neoplasm progression, osteomyelitis. Tretinoin dosage: . During the same period patient was treated with DAUNORUBICIN HCL (For Three Days) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), CYTARABINE (Continous Infusion) (View Cytarabine Review and Cytarabine Label ), MERCAPTOPURINE (View Mercaptopurine Review and Mercaptopurine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ). Patient was hospitalized.

6295843-6 | Aspartate Aminotransferase Abnormal, Bronchopulmonary Aspergillosis, Diarrhoea, Hepatic Function Abnormal
Patient was taking Tretinoin (View Usage). Patient experienced the following unwanted or unexpected effects: aspartate aminotransferase abnormal, bronchopulmonary aspergillosis, diarrhoea, hepatic function abnormal on Jul 20, 2009 from JAPAN Additional patient health information: Male patient , 65 years of age, . Tretinoin dosage: . During the same period patient was treated with MERCAPTOPURINE (View Mercaptopurine Review and Mercaptopurine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), IDARUBICIN HCL (View Idarubicin Hcl Review and Idarubicin Hcl Label ), MITOXANTRONE (View Mitoxantrone Review and Mitoxantrone Label ).

6189741-6 | Febrile Neutropenia, Leukaemia Recurrent, Mucosal Inflammation, Nausea, No Therapeutic Response, Oesophageal Stenosis, Renal Failure Acute, Respiratory Distress, Retinoic Acid Syndrome
Adverse event was reported on Apr 27, 2009 by a Male patient taking Tretinoin (View Usage) (Dosage: ) was diagnosed with acute promyelocytic leukaemia and. Location: CANADA , 16 years of age, Patient had the following side effects: febrile neutropenia, leukaemia recurrent, mucosal inflammation, nausea (What is nausea?), no therapeutic response, oesophageal stenosis, renal failure acute, respiratory distress, retinoic acid syndrome. During the same period patient was treated with MERCAPTOPURINE (View Mercaptopurine Review and Mercaptopurine Label ), METHOTREXATE (Oral) (View Methotrexate Review and Methotrexate Label ).

6182507-2 | Malignant Neoplasm Progression
on Apr 27, 2009 Male patient from NORWAY , 86 years of age, was treated with Tretinoin (View Usage). After Tretinoin was administered, patient had the following side effects: malignant neoplasm progression. Tretinoin dosage: Received For The First 14 Days; Treatment Repeated Every Third Month.. During the same period patient was treated with VALPROIC ACID (Received Continuous Intravenous Infusions On Day 3.) (View Valproic Acid Review and Valproic Acid Label ), THEOPHYLLINE (Continuous Iv Infusion On Day 3; Dose Adjusted Based On Serum Levels (therapeutic Level: 50-100 Um)) (View Theophylline Review and Theophylline Label ).

6182496-0 | Acute Myeloid Leukaemia, Malignant Neoplasm Progression
on Apr 27, 2009 Male patient from NORWAY , 74 years of age, was treated with Tretinoin (View Usage). Patient experienced the following unwanted or unexpected effects: acute myeloid leukaemia, malignant neoplasm progression. Tretinoin dosage: Received For The First 14 Days; Treatment Repeated Every Third Month.. During the same period patient was treated with VALPROIC ACID (Received Continuous Intravenous Infusions On Day 3.) (View Valproic Acid Review and Valproic Acid Label ), THEOPHYLLINE (Continuous Iv Infusion On Day 3; Dose Adjusted Based On Serum Levels (therapeutic Level: 50-100 Um)) (View Theophylline Review and Theophylline Label ).

6182495-9 | Malignant Neoplasm Progression
Patient was taking Tretinoin (View Usage). Patient had the following side effects: malignant neoplasm progression on Apr 27, 2009 from NORWAY Additional patient health information: Female patient , 70 years of age, . Tretinoin dosage: Received For The First 14 Days; Treatment Repeated Every Third Month.. During the same period patient was treated with VALPROIC ACID (Received Continuous Intravenous Infusions On Day 3.) (View Valproic Acid Review and Valproic Acid Label ), THEOPHYLLINE (Continuous Iv Infusion On Day 3; Dose Adjusted Based On Serum Levels (therapeutic Level: 50-100 Um)) (View Theophylline Review and Theophylline Label ).